BP
OVID icon

BBR Partners’s Ovid Therapeutics OVID Stock Holding History

BBR Partners’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-12,495
Closed -$11.7K – 254
2024
Q4 		$11.7K Hold
12,495
– – ﹤0.01% 247
2024
Q3 		$14.7K Hold
12,495
– – ﹤0.01% 239
2024
Q2 		$9.61K Buy
+12,495
New +$34.8K ﹤0.01% 220

Other funds holding OVID

TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

BBR Partners's OVID Position: Q1 2025 in Review

BBR Partners sold out of Ovid Therapeutics (OVID) in Q1 2025, closing a stake of 12,495 shares — an estimated $11.7K sold.

BBR Partners first reported a position in OVID in Q2 2024 and held it in 3 quarters. The position peaked at $14.7K in Q3 2024. 82 funds tracked by Wall St. Rank hold OVID as of Q1 2025.

  • BBR Partners reported no remaining Ovid Therapeutics position as of Q1 2025 after selling out during the quarter.
  • BBR Partners sold 12,495 Ovid Therapeutics shares in Q1 2025, an estimated $11.7K.
  • BBR Partners first reported a position in Ovid Therapeutics in Q2 2024 and held it in 3 quarters.
  • BBR Partners's Ovid Therapeutics position peaked at $14.7K in Q3 2024.
  • 82 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2025.

Based on BBR Partners's 13F filing for Q1 2025, filed 14 May 2025.